Levels of macrophage colony-stimulating factor (nine of nine patients) and gamma interferon (six of nine patients) in serum were elevated above the range of normal in the acute phase of tsutsugamushi disease. Significant increases in levels of tumor necrosis factor alpha were observed during the convalescent phase in five patients, and they exceeded the levels observed during the acute phase. Hypercytokinemia appeared to be responsible for the emergence of the symptoms of tsutsugamushi disease.
Tsutsugamushi disease is a rickettsial infection that occurs in Southeast Asia; it is also called mite-borne typhus or scrub typhus. Tsutsugamushi disease is also well-known in Japan, and it can spread to become severe and potentially life threatening. The etiologic agent was previously known as Rickettsia tsutsugamushi (6) . Because phenotypic and genotypic differences between this pathogen and other species belonging to the genus Rickettsia were demonstrated, the genus Orientia was proposed for this pathogen (12) . Strains of Orientia tsutsugamushi have been reported to differ in their virulence for experimental animals (3) . However, the virulence of even the same strain of O. tsutsugamushi depends on host factors (2) . For example, patients with a glucose-6-phosphate dehydrogenase deficiency develop tsutsugamushi disease that is relatively severe (14) . This suggests that specific host factors can modify the responses to organisms during rickettsial infection.
To our knowledge, hypercytokinemia in tsutsugamushi disease has not been specifically investigated in a series of patients. The present study investigated nine Japanese patients with confirmed severe O. tsutsugamushi infections to determine the host response with respect to the serum cytokine level. Each of these patients required intensive treatment in the hospital for the control of symptoms and complications. Except for patient 9, each exhibited a persistent fever above 38.5°C, rash, and lymphadenopathy. Their characteristics appear in Tables 1 and 2 . They had complications that included not only high fever and myalgia but also hepatosplenomegaly (patients 1, 2, 4, and 9), liver dysfunction (patients 1, 7, and 9), pulmonary involvement (patients 1 and 9), severe general rash (patient 4), and coma (patient 7). We used the clinical severity scoring system which was presented by Kern et al. (9) for Mediterranean spotted fever with minor modifications to adjust it to tsutsugamushi disease, and four patients (each with a total score of over 5 points) were considered to have very severe tsutsugamushi disease. In brief, the score was calculated as the sum of different point values assigned to specific criteria: central nervous system involvement (1 point), severe myalgia (1 point), radiographically documented pulmonary involvement (1 point), an elevated serum creatinine level of 1.5 to 3.5 mg/dl (1 point) or of Ͼ3.5 mg/dl (2 points), an elevated serum transaminase level of 41 to 100 U/liter (1 point) or of Ͼ100 U/liter (2 points), hepatosplenomegaly (1 point), thrombocytopenia with platelet counts of 100 ϫ 10 9 to 149 ϫ 10 9 /liter (1 point) or of Ͻ100 ϫ 10 9 /liter (2 points), and an elevated level of fibrinogen degradation products (1 point). These scores, with possible total points ranging from 0 to 11, were determined on the basis of laboratory data and major symptoms on admission. The median score for the nine patients in this study on admission was 4, with the range being 1 to 8 (mean Ϯ standard deviation, 4.0 Ϯ 2.2). The interval between disease onset and the initiation of administration of an effective antibiotic was critical to the success of treatment. In this study, a relationship between disease severity (as determined by using the clinical scoring system) and the duration of high fever could not be clearly verified, but a slight correlation was shown (r ϭ 0.76, P Ͻ 0.05). They appeared not to be infected by cytomegalovirus, Epstein-Barr virus, or hepatitis virus, as evidenced by low immunoglobulin M serum titers. Other biochemical studies or diagnostic imaging was used to verify the absence of any underlying disease. A diagnosis of tsutsugamushi disease was made upon determination of a fourfold rise in antibody titer to strains of O. tsutsugamushi (Gilliam or Karp type) in serum as detected by an indirect immunoperoxidase antibody test (17) performed on paired serum samples collected during the acute and convalescent phases.
Sera were frozen within 8 h of being received and were stored at Ϫ80°C until analyzed. In our experience, freezing has no influence on the results on retesting. Serum cytokine levels in the nine patients were routinely determined on admission within 10 days of disease onset, i.e., in the acute phase. In seven patients they were also measured 2 to 5 weeks after the initiation of antirickettsial therapy, i.e., in the convalescent phase. Serum levels of macrophage colony-stimulating factor (M-CSF), gamma interferon (IFN-␥), tumor necrosis factor alpha (TNF-␣), granulocyte colony-stimulating factor (G-CSF), interleukin-1␣ (IL-1␣), and IL-1␤ were determined at the Cellular Technology Institute (Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan). Except for M-CSF, serum cytokine levels were measured by an enzyme-linked immunosorbent assay (Otsuka Pharmaceutical Co. Ltd.) using horseradish peroxidase (10). M-CSF was measured by a radioimmunoassay that determined the binding of 125 I-labeled M-CSF (5). The amount of cytokine in each sample was determined by comparison with a standard curve. Data are reported as the concentrations of each cytokine in the acute and the convalescent phases. Normal values for each cytokine were determined in normal subjects. A paired Student's t test was used for statistical analyses. A P value of Ͻ0.05 was considered statistically significant. Serum M-CSF levels were abnormally elevated in the nine patients during the acute phase of the disease. Increases in serum cytokine levels to readily detectable concentrations were observed for IFN-␥ in six of nine patients, for G-CSF in five of nine patients, and for TNF-␣ in two of nine patients (Table 3) . Changes in serum cytokine concentrations were studied in seven of the nine patients; the other two patients were not tested in the convalescent phase. Serum M-CSF levels was decreased in the seven patients (P ϭ 0.001) to below 2.5 ng/ml, the upper limit of the normal range, during the convalescent phase. The serum IFN-␥ levels of the seven patients were also decreased (P ϭ 0.039); however, during the convalescent phase, five patients exhibited significant increases in serum TNF-␣ levels to concentrations greater than those seen during the acute phase and also greater than 20 pg/ml, the upper limit of the normal range (P ϭ 0.022) (Fig. 1) . No significant correlations between the levels of the different cytokines were demonstrated. No patient exhibited an increase in serum IL-1␣ or IL-1␤ levels during either the acute or the convalescent phase. All nine patients responded well to minocycline (200 mg daily) administered intravenously or orally. The high fever and other symptoms diminished within a few days of initiating the antibiotic therapy.
Host protection against rickettsial infection involves a complex interaction between cell-mediated and humoral factors (8) . The patient with the most severe illness (patient 9), for whom the disease was nearly fatal, showed increases in circulating cytokines (M-CSF, G-CSF, and TNF-␣) and hemophagocytic syndrome (HPS) (7). A previous report described a virus-associated hemophagocytic syndrome, the best-known type of infection-associated HPS; its development was correlated with serum cytokine levels (4). Details on the immune protective mechanisms against rickettsial infection, including the activation of cytokines, are not fully understood. However, T-lymphoid cells (8) and macrophages (11) are believed to be important in protecting the host against rickettsial infection. For example, the peak activation of macrophages occurs during the active process of rickettsial clearance (11) . M-CSF may be particularly important in tsutsugamushi disease, because all patients in this study showed high levels of M-CSF in their sera during the acute phase. TNF-␣ is a well-characterized cytokine that mediates a wide range of cellular immune responses to infection or inflammation (1). TNF-␣ has been shown to be important in host defenses against a variety of intracellular pathogens (13, 15, 16) . These cytokines may be involved in the development of a condition such as HPS during the advanced stage of tsutsugamushi disease in some patients. This disorder represents a hyperreaction of the immune system that is mediated by an upregulation of the cytokine network. Some tsutsugamushi disease patients with high severity scores (Ն5) (patients 1, 4, 7, and 9 in this study) showed elevated TNF-␣ levels during the convalescent phase relative to their acute-phase levels; however, two patients (7 and 9) did not show high levels of TNF-␣ during the acute phase. This cytokine may thus have a specific role in disease progression. In the acute phase, each of the four patients with high severity scores had high levels of M-CSF, and two of these patients (1 and 9) also had elevated G-CSF levels (Table 3) . A detailed study of the activation of the cytokine network in patients with tsutsugamushi disease may increase our understanding of why some people become sicker than others when they are infected with the same organism.
